lenalidomide

Health Canada has approved epcoritamab for use in combination with lenalidomide and rituximab to treat patients with relapsed or refractory follicular lymphoma. The regulatory decision gives Canadian clinicians and patients a new combination therapy option for this form of lymphoma that has returned or stopped responding to earlier treatment. Hematology news outlets are reporting the approval, which expands the treatment landscape for follicular lymphoma patients in Canada.